Qian Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qian Wen has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Chun Wan
Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University
1 shared publication- Dan Luo
Department of Dermatology the First Affiliated Hospital of Nanjing Medical University Nanjing China
1 shared publication - Fuqiang Wen
Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
1 shared publication Gajin Park
Department of Dermatology the First Affiliated Hospital of Nanjing Medical University Nanjing China
1 shared publicationHequn Huang
Department of Dermatology, No. 1 Hospital and Key Laboratory of Dermatology Ministry of Education Anhui Medical University Hefei China
1 shared publicationJing Zhu
Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University
1 shared publication
Latest Publications
- Open Access
- 1 May 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (6) , e1690
Costello syndrome with special cutaneous manifestations and HRAS G12D mutation: A case report and literature review
Background: Costello syndrome (CS, OMIM 218040) is a rare congenital disorder caused by mutations in HRAS. Previous studies reported that approximately 80% of patients with CS share the same pathogenic variant in HRAS gene in c.34G> A (p.G12S). Here, we report a CS patient with c.34G> A (p.G12D) variant in HRAS gene and she presented with special manifestation.Methods and Results: We describe a 31‐year‐old female patient who presented with distinctive facial appearance, intellectual disability, dental abnormalities, hyperkeratosis of palmer and planter, loose skin at birth, papillomata on the face and nipples. The whole‐exome sequencing (WES) technology provided by Haotian Biotechnology (China) confirmed p.G12D variant in HRAS gene. To elucidate the typical features of CS with p.G12D variant, we further reviewed these previously reported cases and found that patients with G12D variant died within three months after birth due to multiple organ failure. They had the typical facial characteristics, failure to thrive, skin and cardiac abnormalities, and gene testing confirmed the diagnosis of CS.Conclusion: To the best of our knowledge, this is the first article to report a patient with a p.G12D variant that had special but mild manifestation. Moreover, this report and literature review casts new light on the clinical features of p.G12D variant.
- 1 May 2021
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 9 (6) , e1690
Open AccessCostello syndrome with special cutaneous manifestations and HRAS G12D mutation: A case report and literature review
Background: Costello syndrome (CS, OMIM 218040) is a rare congenital disorder caused by mutations in HRAS. Previous studies reported that approximately 80% of patients with CS share the same pathogenic variant in HRAS gene in c.34G> A (p.G12S). Here, we report a CS patient with c.34G> A (p.G12D) variant in HRAS gene and she presented with special manifestation.Methods and Results: We describe a 31‐year‐old female patient who presented with distinctive facial appearance, intellectual disability, dental abnormalities, hyperkeratosis of palmer and planter, loose skin at birth, papillomata on the face and nipples. The whole‐exome sequencing (WES) technology provided by Haotian Biotechnology (China) confirmed p.G12D variant in HRAS gene. To elucidate the typical features of CS with p.G12D variant, we further reviewed these previously reported cases and found that patients with G12D variant died within three months after birth due to multiple organ failure. They had the typical facial characteristics, failure to thrive, skin and cardiac abnormalities, and gene testing confirmed the diagnosis of CS.Conclusion: To the best of our knowledge, this is the first article to report a patient with a p.G12D variant that had special but mild manifestation. Moreover, this report and literature review casts new light on the clinical features of p.G12D variant.
- Open Access
- 1 January 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (1) , 1199-1207
Performance of COPD population screener questionnaire in COPD screening: a validation study and meta-analysis
This study aimed to validate the chronic obstructive pulmonary disease (COPD) Population Screener (COPD-PS) questionnaire as a screening tool in a cohort of Chinese subjects who underwent a health examination, and to summarise its overall performance through a meta-analysis. We enrolled 997 subjects aged ≥40 years who underwent a health examination, both lung function and COPD-PS data were collected. The screening performance of COPD-PS was evaluated with a receiver operating characteristic (ROC) curve analysis, using the area under the curve (AUC) to assess the screening accuracy. A standard diagnostic meta-analysis was used to summarise the screening performance of COPD-PS for COPD. Of the 997 subjects, 157 were identified as having COPD. The COPD-PS score was significantly higher in COPD patients than controls (5.03 ± 5.11 vs. 2.72 ± 1.80, p < .001). At a cut-off of 4, the sensitivity and specificity of COPD-PS for identifying COPD were 74.52 and 70.24%, respectively, with an AUC of 0.79. Eight studies (including this study) were included in this meta-analysis. The pooled estimates for COPD-PS were as follows: sensitivity of 0.66 (95% CI: 0.47–0.63), specificity of 0.86 (95% CI: 0.84–0.89), positive likelihood ratio of 3.00 (95% CI: 1.65–5.47), negative likelihood ratio of 0.43 (95% CI: 0.35–0.52) and diagnostic odds ratio of 7.24 (95% CI: 3.91–13.40). The AUC of the summary ROC curve was 0.78. COPD-PS appears to be a useful tool for screening individuals with a high risk of COPD and guiding the selection of individuals for subsequent spirometry examination.
- 1 January 2021
- Published by Taylor & Francis in Annals of Medicine
- Vol. 53 (1) , 1199-1207
Open AccessPerformance of COPD population screener questionnaire in COPD screening: a validation study and meta-analysis
This study aimed to validate the chronic obstructive pulmonary disease (COPD) Population Screener (COPD-PS) questionnaire as a screening tool in a cohort of Chinese subjects who underwent a health examination, and to summarise its overall performance through a meta-analysis. We enrolled 997 subjects aged ≥40 years who underwent a health examination, both lung function and COPD-PS data were collected. The screening performance of COPD-PS was evaluated with a receiver operating characteristic (ROC) curve analysis, using the area under the curve (AUC) to assess the screening accuracy. A standard diagnostic meta-analysis was used to summarise the screening performance of COPD-PS for COPD. Of the 997 subjects, 157 were identified as having COPD. The COPD-PS score was significantly higher in COPD patients than controls (5.03 ± 5.11 vs. 2.72 ± 1.80, p < .001). At a cut-off of 4, the sensitivity and specificity of COPD-PS for identifying COPD were 74.52 and 70.24%, respectively, with an AUC of 0.79. Eight studies (including this study) were included in this meta-analysis. The pooled estimates for COPD-PS were as follows: sensitivity of 0.66 (95% CI: 0.47–0.63), specificity of 0.86 (95% CI: 0.84–0.89), positive likelihood ratio of 3.00 (95% CI: 1.65–5.47), negative likelihood ratio of 0.43 (95% CI: 0.35–0.52) and diagnostic odds ratio of 7.24 (95% CI: 3.91–13.40). The AUC of the summary ROC curve was 0.78. COPD-PS appears to be a useful tool for screening individuals with a high risk of COPD and guiding the selection of individuals for subsequent spirometry examination.